Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,535.00    -5.00 (-0.32%)
Bid:
1,535.00
Ask:
1,537.00
Spread: 2.00 (0.13%)
Market Cap: £3.23b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

26 Sep 2016 10:18

RNS Number : 8036K
Hikma Pharmaceuticals Plc
26 September 2016
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities

The attached individual notification made under article 19.1 of the Market Abuse Regulation ("MAR") relates to the purchase by Darhold Limited of Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Chairman and Chief Executive, Vice Chairman and a Non-executive Director are directors of and shareholders in Darhold Limited. This announcement is made in accordance with article 19.3 of MAR.

Said Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Chairman and Chief Executive Officer / PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Acquisition by Darhold Limited of 50,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Chairman and Chief Executive is a director of and shareholder in Darhold Limited with an equity interest of 21.49%.

c)

Price(s) and volume(s)

Price(s): £20.99

Volume(s): 50,000

d)

Aggregated information

Aggregated volume: 50,000

Price: £20.99

e)

Date of the transaction

23 September 2016

f)

Place of the transaction

London Stock Exchange (XLON)

 Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman / PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Acquisition by Darhold Limited of 50,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Executive Vice Chairman is a director of and shareholder in Darhold Limited with an equity interest of 10.82%.

c)

Price(s) and volume(s)

Price(s): £20.99

Volume(s): 50,000

d)

Aggregated information

Aggregated volume: 50,000

Price: £20.99

e)

Date of the transaction

23 September 2016

f)

Place of the transaction

London Stock Exchange (XLON)

Mohammed 'Ali' Al-Husry

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mohammed 'Ali' Al-Husry

2

Reason for the notification

a)

Position/status

Non-executive Director/ PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Acquisition by Darhold Limited of 50,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Non-Executive Director is a director of and shareholder in Darhold Limited with an equity interest of 7.95%.

c)

Price(s) and volume(s)

Price(s): £20.99

Volume(s): 50,000

d)

Aggregated information

Aggregated volume: 50,000

Price: £20.99

e)

Date of the transaction

23 September 2016

f)

Place of the transaction

London Stock Exchange (XLON)

 

Peter Speirs, Company Secretary, Responsible for releasing this announcement

26 September 2016

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHGCGDCLBDBGLL
Date   Source Headline
2nd Oct 20173:36 pmRNSTotal Voting Rights
28th Sep 20173:29 pmRNSHolding(s) in Company
25th Sep 201711:27 amRNSHolding(s) in Company
14th Sep 20173:52 pmRNSHolding(s) in Company
25th Aug 20178:41 amRNSHolding(s) in Company
17th Aug 20177:00 amRNSHikma announces licensing agreement with Takeda
17th Aug 20177:00 amRNSHalf-year Report
10th Aug 201710:05 amRNSDirector/PDMR Shareholding
10th Aug 201710:02 amRNSDirector/PDMR Shareholding
9th Aug 20179:54 amRNSDirector/PDMR Shareholding
4th Aug 20179:56 amRNSHolding(s) in Company
3rd Aug 20172:22 pmRNSNotice of Results
24th Jul 201710:53 amRNSHolding(s) in Company
4th Jul 201711:02 amRNSTotal Voting Rights
3rd Jul 20173:03 pmRNSHolding(s) in Company
30th Jun 20174:11 pmRNSHolding(s) in Company
26th Jun 20177:00 amRNSLeadership and Structural Changes to US Business
12th Jun 20174:31 pmRNSDirector/PDMR Shareholding
2nd Jun 20174:51 pmRNSTotal Voting Rights
31st May 20179:38 amRNSDirector/PDMR Shareholding
19th May 20172:44 pmRNSResult of AGM
19th May 20177:00 amRNSTrading Statement
15th May 20173:30 pmRNSDirector/PDMR Shareholding
11th May 20177:50 amRNSHikma update on ANDA for generic Advair Diskus
8th May 20179:23 amRNSChange of Registered Address
3rd May 20175:23 pmRNSTotal Voting Rights
3rd May 201710:37 amRNSChange of Registered Office
28th Apr 20172:30 pmRNSDirector/PDMR Shareholding
28th Apr 20171:57 pmRNSDirector/PDMR Shareholding
24th Apr 20173:35 pmRNSDirector/PDMR Shareholding
13th Apr 20178:58 amRNSDirector/PDMR Shareholding
13th Apr 20178:43 amRNSDirector/PDMR Shareholding
13th Apr 20178:42 amRNSDirector/PDMR Shareholding
13th Apr 20178:41 amRNSDirector/PDMR Shareholding
13th Apr 20178:36 amRNSDirector/PDMR Shareholding
11th Apr 20174:01 pmRNSDirector/PDMR Shareholding
7th Apr 201711:55 amRNSAnnual Financial Report
6th Apr 20177:00 amRNSHikma enters into settlement agreement with Jazz
3rd Apr 20173:59 pmRNSTotal Voting Rights
3rd Apr 20173:56 pmRNSBlock listing Interim Review
27th Mar 201711:13 amRNSHolding(s) in Company
23rd Mar 20179:30 amRNSDirector/PDMR Shareholding
15th Mar 20177:00 amRNSFinal Results
10th Mar 20177:30 amRNSHikma launches Desvenlafaxine Succinate Tablets
8th Mar 20174:01 pmRNSNotice of Results
8th Mar 20171:30 pmRNSDirector/PDMR Shareholding
1st Mar 20172:38 pmRNSTotal Voting Rights
13th Feb 20179:19 amRNSLicensing agreement with Orion for Easyhaler®
6th Feb 20172:27 pmRNSTotal Voting Rights
6th Feb 201712:47 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.